Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use | Zendy

Alexander M. Sherwood | Zendy; Romain Claveau | Zendy; Rafael Lancelotta | Zendy; Kristi W. Kaylo | Zendy; Kelsey Lenoch | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use

Author(s) -

Alexander M. Sherwood,

Romain Claveau,

Rafael Lancelotta,

Kristi W. Kaylo,

Kelsey Lenoch

Publication year - 2020

Publication title -

acs omega

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.779

H-Index - 40

ISSN - 2470-1343

DOI - 10.1021/acsomega.0c05099

Subject(s) - yield (engineering) , high performance liquid chromatography , chemistry , salt (chemistry) , active ingredient , impurity , process development , natural product , combinatorial chemistry , chromatography , organic chemistry , materials science , pharmacology , process engineering , medicine , engineering , metallurgy

To support clinical use, a multigram-scale process has been developed to provide 5-MeO-DMT, a psychedelic natural product found in the parotid gland secretions of the toad, Incilius alvarius . Several synthetic routes were initially explored, and the selected process featured an optimized Fischer indole reaction to 5-MeO-DMT freebase in high-yield, from which the 1:1 succinate salt was produced to provide 136 g of crystalline active pharmaceutical ingredient (API) with 99.86% peak area by high-performance liquid chromatography (HPLC) and a net yield of 49%. The report provides in-process monitoring, validated analytical methods, impurity formation and removal, and solid-state characterization of the API essential for subsequent clinical development.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research